Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProcept Biorobotics Corp

Procept Biorobotics Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
22.8 USD 0.43 ( 1.92%)
Last update at 2026-11-10T15:17:00Z
VOLUME
165903
Market Cap
3212.94M

Momentum Score

…

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
21.89
Low
23.12
High
52 Week Price Range
47.04
Low
103.81
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Procept Biorobotics makes the Aquablation robotic waterjet system for treatment of benign prostatic hyperplasia and sells associated procedure consumables to hospitals and urology practices. Long-term growth may be driven by an aging patient population, wider adoption of minimally invasive prostate therapies, international expansion and improving reimbursement, and investors may view the company as attractive for its differentiated robotics niche and recurring consumable revenue.

Material risks include slower-than-expected clinical adoption, reimbursement shortfalls, competition from established and emerging urology technologies and the potential need for additional capital if operating losses continue.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
22.37
Dividend Yield
-
Revenue TTM
249.12M
Revenue Per Share
4.69
Gross Profit TTM
156.23M
Debt / Equity
0.20
ROE
-27.62%
Net Debt
-253.47M
ROCE
-16.79%
Diluted EPS TTM
-1.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -87.15M -59.85M -53.02M -41.98M
Net income -93.58M -62.38M -58.26M -42.65M
Selling general administrative 88.83M 51.04M 30.27M 28.52M
Gross profit 37.09M 15.87M -1.25M -1.89M
Reconciled depreciation 2.84M 3.32M 2.86M 1.49M
Ebit -80.72M -54.16M -47.80M -43.55M
Ebitda -78.71M -54.04M -44.78M -40.95M
Depreciation and amortization 2.01M 0.12M 3.02M 2.60M
Non operating income net other - 0.12M - -
Operating income -80.72M -54.16M -47.80M -43.55M
Other operating expenses 155.74M 88.64M 55.52M 49.72M
Interest expense 5.18M 5.81M 5.26M 0.72M
Interest income 2.50M 0.12M 0.18M 1.15M
Net interest income -2.69M -5.69M -5.08M 0.42M
Income tax expense 6.43M 2.53M 5.24M 0.68M
Total revenue 75.01M 34.47M 7.72M 6.17M
Total operating expenses 117.81M 70.03M 46.55M 41.66M
Cost of revenue 37.93M 18.61M 8.97M 8.05M
Total other income expense net -6.43M -5.69M -5.22M 1.57M
Net income from continuing ops -87.15M -59.85M -53.02M -41.98M
Net income applicable to common shares -87.15M -59.85M -53.02M -41.98M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 534.02M 404.72M 309.33M 337.02M 125.97M
Intangible assets 0.93M 1.20M 1.48M 1.75M -
Other current assets 8.45M 5.21M 6.17M 4.24M 0.73M
Total liab 131.80M 123.97M 112.26M 69.93M 308.87M
Total stockholder equity 402.22M 280.75M 197.07M 267.09M -182.89M
Deferred long term liab - - - 1.50M -
Other current liab 29.56M 25.09M 20.91M 11.08M 6.79M
Common stock - - - -337.02M -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -545.99M -454.57M -348.68M -261.52M -201.67M
Other liab - - - 0.20M 0.20M
Other assets - 0.00M 3.09M 0.78M 0.78M
Cash 333.73M 257.22M 221.86M 304.32M 100.13M
Total current liabilities 53.13M 45.93M 35.29M 16.24M 14.53M
Current deferred revenue 9.56M 5.66M 2.85M 1.02M 0.23M
Net debt -253.47M -178.02M -144.54M -250.22M -45.37M
Short term debt 1.91M 1.68M 2.13M 2.10M 6.26M
Short long term debt - - - - 4.55M
Short long term debt total 80.25M 79.20M 77.32M 54.10M 54.76M
Other stockholder equity 948.21M 735.24M 545.75M 191.64M 18.79M
Property plant equipment - - 32.14M 8.32M 12.91M
Total current assets 481.84M 350.57M 272.63M 326.17M 110.26M
Net tangible assets - - 195.59M 265.34M -184.92M
Net receivables 83.50M 48.38M 15.27M 4.46M 1.55M
Long term debt 51.47M 51.34M 51.21M 50.00M 44.41M
Inventory 56.17M 39.76M 28.54M 13.15M 7.48M
Accounts payable 10.03M 13.50M 9.39M 2.03M 1.24M
Accumulated other comprehensive income - 0.08M -0.01M -0.05M -0.01M
Retained earnings total equity - - - -261.52M -
Non currrent assets other 5.59M 0.92M 3.09M 0.78M 0.78M
Non current assets total 52.17M 54.15M 36.70M 10.85M 15.71M
Capital lease obligations 28.78M 27.86M 26.10M 4.10M 5.80M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2.65M -0.59M -0.23M 50.76M
Change to liabilities 5.79M 6.17M -0.08M -0.49M
Total cashflows from investing activities -2.65M -0.59M -0.23M 43.15M
Net borrowings 1.20M 1.20M 24.68M 24.53M
Total cash from financing activities 3.61M 262.12M 106.77M 26.53M
Change to operating activities 8.78M 2.73M 3.21M 1.51M
Net income -87.15M -59.85M -53.02M -41.98M
Change in cash -79.42M 204.19M 58.20M 25.86M
Begin period cash flow 305.10M 100.91M 42.71M 16.85M
End period cash flow 225.67M 305.10M 100.91M 42.71M
Total cash from operating activities -80.38M -57.33M -48.34M -43.82M
Issuance of capital stock 0.00M 257.07M 76.49M 0.00M
Depreciation 2.84M 3.32M 2.86M 1.49M
Change to inventory -15.25M -6.12M -3.10M -5.07M
Change to account receivables -10.81M -2.91M -0.51M 0.52M
Sale purchase of stock 2.41M 177.41M - -
Other cashflows from financing activities 50.20M 89.75M -0.23M 43.15M
Change to netincome 15.42M 4.45M 2.30M 0.20M
Capital expenditures 2.65M 0.59M 0.23M 7.61M
Change receivables - -2.91M - -
Cash flows other operating - -2.38M - -
Cash and cash equivalents changes - 204.19M - -
Change in working capital -11.49M -4.71M -0.48M -3.53M
Stock based compensation 10.34M 3.80M 2.17M 1.99M
Other non cash items 5.08M -0.34M -0.10M -1.80M
Free cash flow -83.03M -57.93M -48.58M -51.43M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRCT
Procept Biorobotics Corp		 0.43
1.92%		 22.80 - - 12.90 8.26 11.96 -24.58
ABT
Abbott Laboratories		 -1.17
1.06%		 109.34 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -1.38
1.34%		 101.42 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -6.18
1.90%		 319.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -0.98
1.99%		 48.27 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Procept Biorobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

150 Baytech Drive, San Jose, CA, United States, 95134

650 232 7200

https://www.procept-biorobotics.com

756

Name Title Year Born
Dr. Reza Zadno Ph.D. Pres, CEO & Director 1955
Mr. Kevin Waters Exec. VP & CFO 1977
Mr. Hisham Shiblaq Exec. VP & Chief Commercial Officer 1976
Mr. Mohan F. Sancheti Sr. VP of Operations 1964
Ms. Alaleh Nouri EVP, Chief Legal Officer & Corp. Sec. 1979
Ms. Minni Vittal Sr. VP & Chief People Officer NA
Mr. Bijesh Chandran Sr. VP of Regulatory Affairs & Quality Assurance NA
Mr. Barry Templin Sr. VP of Clinical & Medical Affairs NA
Dr. Thomas J. Yorkey Ph.D. Sr. VP of R&D 1962
Dr. Reza Zadno Ph.D. President, CEO & Director 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

QTWO
CAD 1.78
+10.56%
NEO
CAD 27.77
+5.91%
CGI
CAD 52.81
+4.78%
PET
CAD 22.34
+3.81%
QBR-A
CAD 77.96
+2.40%
GFL
CAD 57.98
-10.54%
MUX
CAD 21.12
-7.53%
BYN
CAD 1.58
-7.06%
BRVO
CAD 2.23
-6.89%
ITR
CAD 3.12
-6.87%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…